• AAPL 169.02
  • TSLA 162.13
  • AMZN 176.59
  • MSFT 409.06
  • INTC 34.5
  • EURUSD 1.07
Overview Fundamentals API Earnings EOD API Sample Code Pricing
Register now
Free trial

No credit cards required

Get free API key
  1. Supported exchanges /
  2. NASDAQ /
  3. PHAR.NASDAQ

Pharming Group NV (PHAR NASDAQ) stock market data APIs

$9.73 -0.1(-1%) as of April 24, 2024

Pharming Group NV Financial Data Overview

9.83
9.73
-
9.89
9.625
9.27-16.71
647 M
67 344 K
245 M
-0.0406
0.735
Our easy-to-use no-coding solutions help you get the data effortlessly:
Excel Financial Add-In Google Sheets Financial Add-In Python
APIs SDK Windows Downloader

No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.

General: {
Code: 'PHAR',
Type: 'Common Stock',
Name: 'Pharming Group NV',
Exchange: 'NASDAQ',
CurrencyCode: 'USD',
CurrencyName: 'US Dollar',
CurrencySymbol: '$',
CountryName: 'USA',
CountryISO: 'US',
ISIN: NULL,
CUSIP: NULL,
CIK: '1828316',
EmployerIdNumber: NULL,
FiscalYearEnd: 'December',
IPODate: '2020-12-23',
InternationalDomestic: NULL,
Sector: 'Healthcare',
Industry: 'Biotechnology',
HomeCategory: 'Domestic',
IsDelisted: false,
}

Pharming Group NV Fundamental Data is available in our Financial Data APIs

  • Net Revenue 245 M
  • EBITDA -15 289 000
  • Earnings Per Share -0.16
  • Income Statements
  • Balance Sheets
  • Cash flows
Fundamental data package from $59.99 See full price
Get sample
of Fundamental API Data

Get Pharming Group NV Earnings via APIs

  • Latest Release 2024-03-14
  • EPS/Forecast 0.0045

Get Pharming Group NV End-of-day Data via APIs

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends

Get Pharming Group NV latest news via APIs

Pharming announces first patient dosed in pediatric clinical trial for children aged 1 to 6 years for leniolisib

The multinational Phase III study is evaluating a new pediatric granulated formulation of leniolisib in children aged 1 to 6 years with APDS, a rare primary immunodeficiency Leiden, The Netherlands, ...
  • AMSTERDAM STOCK EXCHANGE:PHARM
  • CLINICAL STUDY
  • EUROPEAN REGULATORY NEWS
  • OTHER NEWS
  • PHARMING GROUP N.V

Pharming announces first patient dosed in pediatric clinical trial for children aged 1 to 6 years for leniolisib

Pharming Group N.V. The multinational Phase III study is evaluating a new pediatric granulated formulation of leniolisib in children aged 1 to 6 years with APDS, a rare primary immunodeficiency Leid...
Do you have any questions?
support@eodhistoricaldata.com